Cogent Biosciences (COGT) Other Operating Expenses (2019 - 2020)
Cogent Biosciences (COGT) posted quarterly Other Operating Expenses of $23000.0 for Q4 2020, up 675.0% year-over-year from $2967.7 in Q1 2020, and down 99.69% quarter-over-quarter from $7.5 million in Q3 2020.
Cogent Biosciences (COGT) Other Operating Expenses (2019 - 2020) Analysis & Trends
Cogent Biosciences (COGT) has reported Other Operating Expenses for 2 consecutive years, with $23000.0 the latest figure, recorded in Q4 2020.
- In Q4 2020, Other Operating Expenses rose 675.0% year-over-year to $23000.0; the TTM figure through Sep 2021 stood at $23000.0 (down 99.69% YoY), while the FY2020 annual figure was $7.5 million, up 9506.41% from the prior year.
- Other Operating Expenses eased to $23000.0 in Q4 2020 per COGT's latest filing, from $7.5 million in the prior quarter.
- Across five years, Other Operating Expenses topped out at $7.5 million in Q3 2020 and bottomed at -$4000.0 in Q4 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Cogent Biosciences | 6.58 Bn | 6.58 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2020 | 23,000.00 |
| Sep 30, 2020 | 7.46 Mn |
| Dec 31, 2019 | -4,000.00 |
| Sep 30, 2019 | 82,000.00 |